12

Click here to load reader

Manejo, Quién?

Embed Size (px)

DESCRIPTION

Simposium de Càncer de Colon V Jornadas de Aniversario Dr. Juan Manuel Medina Castro

Citation preview

Page 1: Manejo, Quién?

[email protected]

MANEJO….. ¿QUIEN?

20 Agosto 2010

COE ISSEMyM - Toluca

Dr. Juan Manuel Medina Castro

[email protected]

Page 2: Manejo, Quién?

[email protected]

Clínica de Carcinomatosis Peritoneal

Factores Pronóstico

Page 3: Manejo, Quién?

[email protected]

Clínica de Carcinomatosis Peritoneal

Invasión transmural

Page 4: Manejo, Quién?

[email protected]

Clínica de Carcinomatosis Peritoneal

Ganglios

El número mínimo de ganglios resecados y evaluados por patología para poder afirmar o negar su involucro

12

Colon and rectum. In: American Joint Committee on Cancer.: AJCC Cancer Staging Manual. 6th ed.

New York, NY: Springer, 2002, pp 113-124

Compton CC, Greene FL: The staging of colorectal cancer: 2004 and beyond. CA Cancer

J Clin 54 (6): 295-308, 2004 Nov-Dec

Swanson RS, Compton CC, Stewart AK, et al.: The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 10 (1): 65-71, 2003 Jan-Feb

Le Voyer TE, Sigurdson ER, Hanlon AL, et al.: Colon cancer survival is associated with

increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J

Clin Oncol 21 (15): 2912-9, 2003

Prandi M, Lionetto R, Bini A, et al.: Prognostic evaluation of stage B colon

cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann

Surg 235 (4): 458-63, 2002

Tepper JE, O'Connell MJ, Niedzwiecki D, et al.: Impact of number of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 19 (1):

157-63, 2001

Page 5: Manejo, Quién?

[email protected]

Clínica de Carcinomatosis Peritoneal

Micro metástasis

¿Porqué 40% de los EC II recurren?

Hasta 30% de micromestástasis

El estudio completo es con inmuno-histoquímica

SV a 5 años 90% vs 70% (EC II)

SV a 5 años 75% vs 60% (EC III)

Prognostic impact of micrometastases in colon cancer: interim results of a

prospective multicenter trial. - Bilchik AJ - Ann Surg - 01-OCT-2007; 246(4): 568-75;

discussion 575-7

Prognostic value of the detection of lymph node micrometastases in

colon cancer. - Bosch Roig CE - Clin Transl Oncol - 01-SEP-2008; 10(9):

572-8

Yasuda K,AdachiY, ShiraishiN, et al. Pattern of lymphnode micrometastasis andprognosisof patients with colorectal cancer. Ann Surg

Oncol 2001;8:300–4.

Page 6: Manejo, Quién?

[email protected]

Clínica de Carcinomatosis Peritoneal

Invasión linfovascular

Que % de patólogos lo reportan?

Que % de cirujanos saben que es un FP

Cual es la traducción clínica?

SV a 5 años de 16% vs 3%

Prognostic value of the detection of lymph node micrometastases in

colon cancer. - Bosch Roig CE - Clin Transl Oncol - 01-SEP-2008; 10(9):

572-8

Newland RC, Dent OF, Lyttle MN, et al. Pathologic determinants of survival associated with

colorectal cancer with lymph node metastases: a multivariate analysis of 579 patients.

Cancer 1994;73:2076–82.

Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer: Collegeof American Pathologists Consensus Statement

1999. Arch Pathol Lab Med 2000;124:979–94.

Page 7: Manejo, Quién?

[email protected]

Clínica de Carcinomatosis Peritoneal

Enfermedad residual

Principal factor pronóstico en enfermedad avanzada.

Relación inversa entre volumen de enfermedad residual y sobrevida.

Compton CC, Fielding LP, Burgart LJ, et al. Prognostic factors in colorectal cancer: Collegeof American Pathologists Consensus Statement

1999. Arch Pathol Lab Med 2000;124:979–94.

Swanson RS, Compton CC, Stewart AK, et al.: The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 10 (1): 65-71, 2003 Jan-Feb

Page 8: Manejo, Quién?

[email protected]

Clínica de Carcinomatosis Peritoneal

Enfermedad residual

Cirujano general Cirujano-oncólogo

Citorreducción óptima = 25-55%

Citorreducción completa = 8-27%

Citorreducción completa = 86%

Por cada cm de citorreducción se aumenta

la SV 10%

Rober E Brostow, Beth Y Karlan.

Ed. Taylor and Francis 2006

Page 9: Manejo, Quién?

[email protected]

Clínica de Carcinomatosis Peritoneal

Grado Histológico

Wiggers T, Arends JW, Volovics A. Regression analysis of clinical and pathological factors

in colorectal cancer after curative resections. Dis Colon Rectum 1988;31:33–41.

Page 10: Manejo, Quién?

[email protected]

Clínica de Carcinomatosis Peritoneal

¿Quien?

Aquel que conozca al cáncer

Aquel que ofrezca el tratamiento completo

Aquel que trabaje multidisciplinariamente

Nelson H, Petrelli N, Carlin A, et al.: Guidelines 2000 for colon and rectal cancer surgery. J Natl

Cancer Inst 93 (8): 583-96, 2001

Page 11: Manejo, Quién?

[email protected]

Clínica de Carcinomatosis Peritoneal